Meeting
2023 ASCO Genitourinary Cancers Symposium
Persistent need for systematic biopsy for those on active surveillance for early-stage prostate cancer.
Authors
Mary Fakunle
University of California, San Francisco, San Francisco, CA
Mary Fakunle , Janet E. Cowan , Samuel L. Washington III, Hao G Nguyen , Matthew R. Cooperberg , Peter Carroll
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 322)
DOI
10.1200/JCO.2023.41.6_suppl.322
Abstract #
322
Poster Bd #
K20
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
p2PSA-associated parameters are significant predictors of reclassification of first-year protocol biopsy on active surveillance for early-stage prostate cancer patients: From the PRIAS-JAPAN study.
First Author: Takuma Kato
Poster
2016 ASCO Annual Meeting
Plasma caveolin-1 to predict disease reclassification in men with early stage prostate cancer in active surveillance.
First Author: Spyridon P Basourakos
Poster
2023 ASCO Genitourinary Cancers Symposium
Limited relevance of the “very low risk” prostate cancer classification in the modern era: Results from a large institutional active surveillance cohort.
First Author: Kevin Shee
Poster
2021 ASCO Annual Meeting
A phase II randomized controlled trial of exercise on biochemical progression in men with prostate cancer on active surveillance.
First Author: Dong-Woo Kang